Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/0004—Oxidoreductases (1.)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/0004—Oxidoreductases (1.)
  • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P37/00—Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin

Definitions

• Beta-lactam antibiotics constitute the most important group of antibiotic compounds with a long history of clinical use.
• the prominent ones are the penicillins and cephalosporins.
• Penicillins are naturally produced by various filamentous fungi such as Penicillium (e.g. P. chrysogenum).
• Cephalosporins are naturally produced by various microorganisms such as Acremonium (e.g. A. chrysogenum) and Streptomyces (e.g. Streptomyces clavuligerus)
• Acremonium e.g. A. chrysogenum
• Streptomyces e.g. Streptomyces clavuligerus
• the first two steps in the biosynthesis of penicillin in P. chrysogenum are the condensation of the three amino acids L-5-amino-5-carboxypentanoic acid (L- ⁇ - aminoadipic acid) (A), L-cysteine (C) and L-valine (V) into the tripeptide LLD-ACV, followed by cyclization of this tripeptide to form isopenicillin N.
• L- ⁇ - aminoadipic acid A
• L-cysteine C
• L-valine V
• This compound contains the typical ⁇ -lactam structure.
• the third step involves the replacement of the hydrophilic side chain of L-5- amino-5-carboxypentanoic acid by a hydrophobic side chain by the action of the enzyme acyltransferase (AT).
• AT acyltransferase
• Cephalosporins are much more expensive than penicillins.
• cephalosporins e.g., cephalexin
• Cephalosporin C by far the most important starting material in this respect, is very soluble in water at any pH, thus implying lengthy and costly isolation processes using cumbersome and expensive column technology.
• Cephalosporin C obtained in this way has to be converted into therapeutically used cephalosporins by a number of chemical and enzymatic conversions.
• the methods currently favored in industry to prepare the intermediate 7- amino-deacetoxycephaloporanic acid (7-ADCA) involve complex chemical steps leading to the expansion and derivatization of penicillin G.
• One of the necessary chemical steps to produce 7-ADCA involves the expansion of the 5-membered penicillin ring structure to a 6-membered cephalosporin ring structure (see for instance US 4,003,894).
• This complex chemical processing is both expensive and noxious to the environment. Consequently, there is a great desire to replace such chemical processes with enzymatic reactions such as enzymatic catalysis, preferably during fermentation.
• a key to the replacement of the chemical expansion process by a biological process is the central enzyme in the cephalosporin biosynthetic pathway, expandase.
• the expandase enzyme from the bacterium Streptomyces clavuligerus (S. clavuligerus) was found to carry out, in some cases, penicillin ring expansions. When introduced into P. chrysogenum, it can convert the penicillin ring structure into the cephalosporin ring structure, as described in Cantwell et al., Proc R Soc Lond B (1992) 248:283-289.
• the expandase enzyme has been well characterized (EP-A-0366354) both biochemical and functional, as has its corresponding gene. Both physical maps of the cefE gene (the gene encoding the expandase enzyme of S. clavuligerus - EP-A- 0341892), DNA sequence and transformation studies in P. chrysogenum with cefE have been described.
• the DNA and amino acid sequence of the S. clavuligerus expandase enzyme are represented in SEQ ID NO 1.
• Nocardia lactamdurans N. lactamdurans, formerly S. lactamdurans. Both the biochemical properties of the enzyme and the DNA sequence of the gene encoding the enzyme have been described - see Cortes et al., J Gen Microbiol (1987) 133:3165-3174 and Coque et al., MoI Gen Genet (1993) 236:453-458,respectively
• deacetoxycephalosporin-C is subsequently converted to deacetyl-cephalosporin-C by the enzyme deacetylcephalosporin C synthase also named deacetoxycephalosporin-C hydroxylase or hydroxylase (EC 1.14.11.26 - DACS).
• deacetylcephalosporin C synthase also named deacetoxycephalosporin-C hydroxylase or hydroxylase (EC 1.14.11.26 - DACS).
• Encoding such hydroxylases are named cefF-genes (e.g. see Hsu et al.)
• the expandase found in eukaryotic cells e.g.
• Acremonium chrysogenum can catalyze the direct conversion of penicillin N to deacetoxycephalosporin-C due to possession of both expandase and hydrolyase activity, hence the encoded gene is termed cefEF(see Hsu et al.).
• expandase relates to expandase enzymes (EC
• the expandase enzyme is capable of expanding penicillins with particular side chains to the corresponding 7-ADCA derivative. This feature of the expandase has been exploited in the technology as disclosed in EP-A- 0532341 , WO95/04148 and WO95/04149.
• the conventional chemical in vitro conversion of penicillin G to 7-ADCA has been replaced by the in vivo conversion of certain 6-aminopenicillanic acid (6-APA) derivatives in recombinant Penicillium chrysogenum strains transformed with an expandase gene.
• EP-A-0532341 teaches the in vivo use of the expandase enzyme in P. chrysogenum, in combination with a adipyl side chain (further referred to as adipyl) as a feedstock, which is a substrate for the acyltransferase enzyme in P. chrysogenum.
• adipyl adipyl side chain
• the removal of the adipyl side chain is described, yielding 7-ADCA as a final product.
• EP-A-540210 teaches the similar production of adipyl-7-ADAC and adipyl-7-ACA.
• the invention provides a mutant expandase that is a variant of a model polypeptide with expandase activity.
• the invention provides a mutant expandase, whereby the mutant expandase has an at least 2.5-fold improved in vitro expandase activity towards adipyl-6-APA in comparison with a model polypeptide with expandase activity.
• the determination of the in vitro expandase activity towards adipyl-6-APA is described in detail in the Materials and Methods.
• the in vitro expandase activity towards adipyl-6-APA of the mutant expandase is improved at least 3-fold, more preferably at least 4-fold, more preferably at least 5-fold, more preferably at least 6-fold, more preferably at least 7-fold, more preferably at least 8- fold, more preferably at least 9-fold, more preferably at least 10-fold, more preferably at least 11 -fold more preferably at least 12-fold, more preferably at least 13-fold, more preferably at least 14-fold, more preferably at least 15-fold more preferably at least 16- fold more preferably at least 17-fold more preferably at least 18-fold more preferably at least 19-fold, more preferably at least 20-fold.
• the invention also provides a mutant expandase which is preferably being modified at least at an amino acid position selected from the group consisting of positions 2, 59, 73, 89, 90, 99, 101, 105, 113, 155, 170, 177, 209, 213, 217, 244, 249, 251 , 277, 278, 280, 281 , 293, 300, 306, 307 and 311 using the amino acid position numbering of the amino acid sequence of the expandase enzyme encoded by the cefE gene of Streptomyces clavuligerus.
• the nucleotide sequence of the cefE gene of Streptomyces clavuligerus as well as the amino acid sequence encoded by said cefE gene are depicted in SEQ ID NO: 1.
• the mutant expandase is modified at least at an amino acid position selected from the group consisting of positions 2, 59, 89, 90, 99, 105, 113, 170, 177, 209, 213, 217, 249, 251 , 278, 280 and 293. Most preferably, the mutant expandase is modified at least at an amino acid position selected from the group consisting of positions 2, 89, 90, 99, 105, 177, 251 , 278, 280 and 293.
• altered or mutant expandase in the context of the present invention is meant any enzyme having expandase activity, which has not been obtained from a natural source and for which the amino acid sequence differs from the complete amino acid sequence of the natural expandase enzyme.
• the invention provides a mutant expandase whereby the mutant expandase has an at least 2.5-fold improved in vitro expandase activity towards adipyl-6-APA in comparison with a model polypeptide with expandase activity, more preferably at least 3-fold, more preferably at least 4-fold, more preferably at least 5- fold, more preferably at least 6-fold, more preferably at least 7-fold, more preferably at least 8-fold, more preferably at least 9-fold, more preferably at least 10-fold, more preferably at least 11 -fold more preferably at least 12-fold, more preferably at least 13- fold, more preferably at least 14-fold, more preferably at least 15-fold more preferably at least 16-fold more preferably at least 17-fold more preferably
• the mutant expandase is modified at least at an amino acid position selected from the group consisting of positions 2, 59, 89, 90, 99, 105, 113, 170, 177, 209, 213, 217, 249, 251 , 278, 280 and 293. Most preferably, the mutant expandase is modified at least at an amino acid position selected from the group consisting of positions 2, 89, 90, 99, 105, 177, 251 , 278, 280 and 293.
• the activity of expandase can be measured under various conditions.
• the concentration of the substrate (e.g. adipyl-6-APA) in the activity assay determines whether or not the expandase activity is measured under conditions wherein the V max determines the activity (in case the substrate concentration is much higher, e.g. 5-20 fold than the K M of the expandase for its substrate) or under conditions wherein in addition also the K M is determining the activity of the expandase (in case the substrate concentration is roughly equal to or (much) lower - e.g. ⁇ 0,05 - 0.2-fold - than the K M of the expandase for its substrate).
• the improvement factor of the mutant expandases may be measured under these various conditions.
• the modification at an amino acid position may comprise a substitution by another amino acid, selected from the group of 20 L-amino acids that occur in Nature - see Table 2.
• the modification at an amino acid position may comprise a deletion of the amino acid at said position.
• the modification at an amino acid position may comprise a substitution of one or more amino acids at the C-terminal or N-terminal side of said amino acid.
• the model polypeptide with expandase activity as used in the present invention is selected from the group consisting of a polypeptide with expandase activity, preferably having an amino acid sequence according to SEQ ID NO: 1 and polypeptides with expandase activity having an amino acid sequence with a percentage identity with SEQ ID NO: 1 of at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95%, such as the expandase enzymes that are summarized in Table !
• the present invention preferably provides mutant expandases that have modifications at least at o 1 or more amino acid positions selected from the group consisting of 2, 59, 73,
• o 5 or more amino acid positions selected from the group consisting of 2, 73, 89, 90, 155, 213, 249, 278, 281, 293, 300, 306, 307 and 311, more preferably at positions 2+89+281+306+311 or 2+155+281+306+311 or 73+89+213+281+311 or 89+78+218+307+311, 89+281+293+300+311 or 89+249+281+307+311.
• o 6 amino acid positions selected from the group consisting of
• the invention furthermore provides mutant expandases as defined hereinbefore that are variants of the expandase of Streptomyces clavuligerus, the mutant expandase being modified at an amino acid position selected from the group consisting of positions D2, S59, M73, T89, N90, M99, Y101, T105, G113, C155, H170, P177, G209,
• Preferred mutant expandases that are variants of the expandase of Streptomyces clavuligerus have modifications at least at o 1 or more amino acid positions selected from the group consisting of D2, S59, M73, T89, N90, M99, T105, G113, C155, H170, P177, G209, T213, Y217, H244, R249, D251, L277, A278, E280, C281, T293, G300, R306, R307 and A311 o 1 or more amino acid positions selected from the group consisting of D2, S59, T89, N90, M99, T105, G113, H170, P177, G209, T213, Y217, R249, D251 ,
• Preferred modifications at the respective positions in the expandase of Streptomyces clavuligerus are the following (using the one-letter code for amino acids) • D at position 2 according to SEQ ID NO 1 replaced by hydrophilic amino acids Y, N, H, D, Q, E, K, R, S or T, preferably by Y, N, Q or H. Most preferred are replacements D2Y, D2N and D2H. • M at position 73 according to SEQ ID NO 1 replaced by A, V, I, L, N, Q, H, K or R, preferably N, Q, H, L or I. Most preferred are replacements M73H and M73I.
• T at position 89 according to SEQ ID NO 1 replaced by K, R, A, C, P, V, I, L, or M, preferably A, V, I, L, R or K, more preferably A, V or K. Most preferred is replacement T89K.
• N at position 90 according to SEQ ID NO 1 replaced by H, R, K, N, Q, W, S, C, T or Y, preferably K, R, N, S, W. Most preferred are replacements N90W and N90S.
• G at position 113 according to SEQ ID NO 1 replaced by A, P, Q, K, R, E, D or N, more preferably A, D, E, Q, K or R. Most preferred is replacement G113D.
• P at position 177 according to SEQ ID NO 1 replaced by K, E, L, A, V, T, I, more preferably L, A, V, T, I. Most preferred are replacements P177L and P177I.
• T at position 213 according to SEQ ID NO 1 replaced by Q, G, A, V, I, R, S, more preferably G, A, V, I, S. Most preferred is replacement T213A.
• Y at position 217 according to SEQ ID NO 1 replaced by A, V, H, P, T, N or Q, more preferably A, P, N, Q or H. Most preferred is replacement Y217H.
• H at position 244 according to SEQ ID NO 1 replaced by N, Q, K or R, more preferably K or R. Most preferred is replacement H244R.
• R at position 249 according to SEQ ID NO 1 replaced by G, S, T, N, D, Q, E, K, R, H or C, more preferably G, S, D, N or C. Most preferred is replacement R249C.
• R at position 306 according to SEQ ID NO 1 replaced by H or a deletion • R at position 307 according to SEQ ID NO 1 replaced by T, K, A, S, V, G, D, N, Q, E, R, H, I or a deletion, more preferably S, T, K, R, H, I or a deletion. Most preferred are replacements R307T, R307I and R307deletion.
• mutant expandases are the mutant expandases that are summarized in Table 3 and 4.
• the mutant expandases provided by the present invention have an at least 2.5-fold improved expandase activity on adipyl-6- APA as defined before.
• the mutant expandases provided by the present invention have an improved expandase activity on Pen-G of at least 1.5-fold in comparison with a model polypeptide with expandase activity, more preferably at least 3-fold, more preferably at least 4-fold, more preferably at least 5-fold, more preferably at least 6-fold, more preferably at least 7-fold, more preferably at least 8-fold.
• Mutant expandases with an improved activity on Pen-G can be used advantageously in a process for the production of phenylacetyl-7-ADCA as described further below.
• the mutant expandases provided by the present invention have an improved expandase on both adipyl-6-APA as well as Pen-G as defined hereinbefore.
• the present invention also provides mutant expandases with a decreased or even absent expandase activity with iso-penicillin N (iPN).
• iPN iso-penicillin N
• the expandase activity with either adipyl-6-APA or Pen-G is not affected, but more preferably the expandase activity with either adipyl-6-APA or Pen-G or both is improved as defined hereinbefore.
• the advantage of these more preferred mutant expandases is that the decreased or even absent expandase activity with iso-penicillin N (iPN) results in less byproduct in a fermentation process producing adipyl-7-ADCA or phenylacetyl-7- ADCA.
• Preferred mutant expandases have a decreased or even absent expandase activity with iso-penicillin N (iPN) as a substrate optionally combined with an improved expandase activity on ad-6-APA as a substrate and have been modified at position 89 according to the amino acid numbering of SEQ ID No 1. whereby the naturally occurring amino acid has been replaced, preferably by a positively charged amino acid such as lysine, arginine or histidine; most preferred being lysine.
• iPN iso-penicillin N
• a highly preferred mutant expandase is selected from the group consisting of H401, H402, H403, H501, H502, H503, H504, H505, H506, H507, H508, H601, H602, H603, H604, H605, H606, H607, H608, H609, H650, H651 , H652, H653, H654, H655, H656, H657, H658, H659, H660, H661 , H662, G601, G602, G603, G604, G605, G606, G607, G608, G609, G610, G611 , G613, G614, H701, H702, H703, H704, H705, H706 (see Table 3 and 4).
• the invention provides a polynucleotide encoding the mutant expandase of the present invention.
• the polynucleotide encoding the mutant expandase according to the present invention can be any polynucleotide that encodes the proper amino acid sequence according to the invention.
• the polynucleotide of the invention may comprise a coding sequence in which the codon usage for the various amino acids deviates from the codon usage in S. clavuligerus.
• the codon usage may be adapted to the codon usage of a particular host cell, which will or has been transformed with the DNA fragment encoding the altered expandase.
• the invention provides an expression vector or expression cassette comprising the polynucleotide of the invention as defined hereinbefore.
• the invention provides a transformed host cell, transformed with the polynucleotide of the invention or the expression vector or expression cassette of the invention.
• the transformed host cell may be used for the production of the mutant expandase of the invention or the host cell may be used for the production of a beta-lactam compound of interest.
• Host cells for the production of the mutant expandase of the invention are preferably host cells which are known in the art for their efficient protein or enzyme production, either extracellular or intracellular ⁇ , for example microorganisms such as fungi, yeast and bacteria.
• preferred host cells comprise, but are not limited to, the following genera: Aspergillus (e.g. A. niger, A. oryzea), Penicillium (e.g. P. emersonii, P. chrysogenum), Saccharomyces (e.g. S. cerevisiae), Kluyveromyces (e.g. K. lactis), Bacillus (e.g. B. subtilis, B. licheniformis, B.
• Aspergillus e.g. A. niger, A. oryzea
• Penicillium e.g. P. emersonii, P. chrysogenum
• Saccharomyces e.g. S. cerevis
• Host cells for the production of a beta-lactam compound of interest are preferably host cells that are known in the art for their efficient beta-lactam compound production. Examples of preferred host cells comprise, but are not limited to, to the following genera: Penicillium (e.g. P. chrysogenum), Acremonium (e.g. A. chrysogenum), Streptomyces (e.g. S. clavuligerus), Nocardia (e.g. N. lactamdurans), Lysobacter (e.g. L. lactamgenus) and Flavobacterium species.
• Penicillium e.g. P. chrysogenum
• Acremonium e.g. A. chrysogenum
• Streptomyces e.g. S. clavuligerus
• Nocardia e.g. N. lactamdurans
• Lysobacter e.g. L. lactamgenus
• Flavobacterium species Flavobacter
• the invention provides a process for the production of the mutant expandase of the invention comprising cultivating the transformed host cell according to the invention under conditions conducive to the production of the mutant expandase and, optionally, recovering the mutant expandase.
• the recovered mutant expandase may be used advantageously in an in vitro process to produce a desired cephalosporin from a corresponding penicillin, for instance the recovered mutant expandase may be used in a process to produce phenylacetyl-7-ADCA from Pen-G or adipyl-7-ADCA from adipyl -6-APA.
• the invention provides a process for the production of a beta- lactam compound of interest comprising cultivating the transformed host cell according to the invention under conditions conducive to the production of the beta-lactam compound of interest and, optionally, recovering the beta-lactam compound.
• Preferred beta-lactam compounds belong to the group of cephalosporins such as phenylacetyl-7- ADCA, adipyl-7-ADCA, adipyl-7-ADAC and adipyl-7-ACA.
• the invention provides a process for the production of phenylacetyl-7-ADCA or adipyl-7- ADCA by cultivating a selected strain of Penicillium chrysogenum, that has been transformed with a selected polynucleotide of the invention that encodes a mutant expandase of the invention.
• a highly preferred mutant expandase is selected from the group consisting of H401 , H402, H403, H501 , H502, H503, H504, H505, H506, H507, H508, H601, H602, H603, H604, H605, H606, H607, H608, H609, H650, H651, H652, H653, H654, H655, H656, H657, H658, H659, H660, H661 , H662, G601 , G602, G603, G604, G605, G606, G607, G608, G609, G610, G611 , G613, G614, H701 , H702, H703, H704, H705, H706 (see Table 3 and 4).
• a mutant expandase is selected that has a high improvement factor on Pen-G as a substrate.
• a mutant expandase is selected that has a high improvement factor on ad-6-APA as a substrate.
• the invention provides a process for the production of 7-ADCA comprising the process for the production of phenylacetyl-7- ADCA or adipyl-7-ADCA as described herein before, followed by, after optional purification of said 7-ADCA-derivatives, a process step in which the phenylacetyl or adipyl side chain of phenylacetyl-7-ADCA and adipyl-7-ADCA respectively is cleaved off thereby generating 7-ADCA and the liberated side chains acid. Said cleavage can be obtained by chemical means or, more preferably, enzymatically using an acylase enzyme.
• Suitable acylases for the cleavage of the adipyl side chain are obtainable from various Pseudomonas species such as Pseudomonas SY-77 or Pseudomonas SE-83.
• Suitable acylases fro the cleavage of the phenylacetyl side chains are the penicillin acylases from Escherichia coli or Alcaligenes feacalis.
• the invention provides a process for the production of a cephalorin from a corresponding penicillin whereby the expansion of the 5-membered thiazolidine ring of the penicillin to the 6-membered dihydrothiazine ring of the cephalorin occurs in an in vitro process, catalyzed by a mutant expandase of the invention.
• adipyl-6-APA is expanded to the corresponding adipyl-7-ADCA by a mutant expandase of the invention, preferably a mutant expandase that has a high improvement factor adipyl-6-APA as a substrate.
• Pen-G is expanded to the corresponding phenylacetyl-7-ADCA by a mutant expandase of the invention, preferably a mutant expandase that has a high improvement factor on Pen-G as a substrate.
• the process may be followed by, after optional purification of said 7-ADCA-derivatives, a process step in which the side chains of adipyl-7-ADCA and phenylacetyl-7-ADCA are cleaved off thereby generating 7-ADCA and the liberated side chains acid - supra vide.
• the desired end product 7- ADCA can be recovered according to methods known in the art involving chemical or enzymatic cleavage of the side chain of adipyl-7-ADCA or phenylacetyl-7-ADCA and optionally the resulting 7-ADCA can be further purified and/or crystallized.
• the invention provides a method to obtain the mutant expandases of the invention whereby the process comprises the following steps:
• steps 1 and 2 are optionally repeating steps 1 and 2 one or several times using either the gene encoding the model polypeptide with expandase activity or one or more of the mutagenised genes encoding mutant expandases with an improved activity on the suitable substrate.
• Cloning of the gene encoding a model polypeptide with expandase activity can be carried out according to methods known in the art.
• Preferred model polypeptides with expandase activity are selected from the group consisting of a polypeptide with expandase activity obtainable from Streptomyces clavuligerus, preferably having an amino acid sequence according to SEQ ID NO: 1 and polypeptides with expandase activity having an amino acid sequence with a percentage identity with SEQ ID NO: 1 of at least 70%, preferably at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, most preferably at least 95%, such as the expandase enzymes that are summarized in Table 1.
• Any mutagenesis technique can be employed which results in mutations over the entire gene. Suitable techniques are error prone (EP) PCR (Polymerase Chain Reaction) and/or by using saturated Mutation Primer PCR (sMPP) exactly according to WO 03/010183.
• EP error prone
• sMPP saturated Mutation Primer PCR
• Oligonucleotides were synthesized by Invitrogen (Carlsbad CA, US).
• DNA sequencing was carried out by SEQLAB (G ⁇ ttingen, Germany) or by Baseclear (Leiden, The Netherlands).
• Escherichia coli DH 1OB electromax competent cells were obtained from Invitrogen. The protocol was delivered by the manufacturer.
• the ampicillin selection marker in pBAD/Myc- His (commercially available from InvitrogenTM) is replaced by the zeozin selection marker.
• the maltose binding protein is fused to the wild type S. clavuligerus expandase gene and ligated behind the pBAD promoter resulting in the vector pBAD-MH-Zeo-MBP-ScEwt.
• the wild type CefE is exchanged by the library of error prone mutants.
• the expandase E. coli library is plated on Luria-Bertani (LB) medium plates low salt agar + 25 ⁇ g/ml Zeocine and incubated overnight at 37°C.
• Microtitre plates (MTP) with 150 ⁇ l LB low salt medium and 25 ⁇ g/ml Zeocine are inoculated from the plates and incubated 36 hrs at 25°C and 550 rpm.
• CFE Cell free extract
• Selected colonies are inoculated from plate in 10 ml LB low salt + Zeocin 25 ⁇ g/ml and incubated overnight at 37°C, 280 rpm.
• the grown culture is inoculated in 100 ml LB low salt with 25 ⁇ g/ml Zeocine at an optical density (600 nm) between 0.010 and 0.050 (Biochrom Ultraspec 2000).
• the cells are harvested at an optical density at 600 nm between 0.4-0.6.
• arabinose is added (final concentration 0.2%) and induced overnight at 27°C at 220 rpm.
• the cultures are centrifuged, the supernatant is discarded and the pellet is frozen at -20 0 C.
• the fusion product is ligated in the pBAD/MH MBP-ScEwt Dest zeo-zeo vector by an EcoRI/Sa/l digestion. This replaces the wild type expandase gene by the library genes. To prevent significant numbers of wild type constructs, the ligation constructs were digested with Sma ⁇ .
• a total of 300 ⁇ l of a reaction mixture consisting of 50 rtiM Tris/HCI pH 7.5; 1 rtiM DTT; 2.7 rtiM Ascorbate; 0.05 rtiM ATP; 24 rtiM ⁇ -ketoglutarate; 0.06 rtiM FeSO 4 .7H 2 O; 4 rtiM adipyl-6-amino-penicillanic acid (ad-6-APA) was added to 75 ⁇ l CFE and incubated at 29°C for the desired time. Adding 60 ⁇ l maleic acid with 10 g/l EDTA stopped the reaction.
• adipyl-7-amino-desacetoxy- cephalosporinic acid (ad-7-ADCA) was detected using 1 H-NMR. Under these conditions, the expandase activity is measured close to V max conditions since the K M of the S. clavuligeris wild type enzyme for ad-6-APA is ca 0.4 mM. Alternatively, the assay may be carried out using 0.4 mM ad-6-APA ( ⁇ K M of the S. clavuligeris wild type enzyme for ad-6-APA).
• adipyl-6-APA was obtained from 6-APA and adipic acid catalyzed by glutaryl acylase (EC 3.5.1.11).
• adipyl-6-APA can be obtained by culturing for instance a suitable Penicillium chrysogenum strain in the presence of adipic acid as precursor.
• the first generation expandase library was constructed by performing error prone (EP) PCR (Polymerase Chain Reaction) on wild type Streptomyces clavuligerus
• CefE gene (SEQ ID No.1). After screening this library for improved conversion of ad-6-
• APA to ad-7-ADCA 3 different mutant genes were selected.
• the mutants exhibited an improved ad-6-APA expansion activity up to 2.5-fold (H401 , H402, H403: see Table 3).
• the second-generation expandase library was constructed by using saturated Mutation Primer PCR (sMPP) exactly according to WO 03/010183.
• the selected mutant genes from the first generation (H401 , H402 and H403) were used as templates for the construction of the 2 nd generation library.
• the sMPP was performed by using Taq polymerase, thereby introducing additional mutations (random) and increasing the variation of the library. Designed primers annealed at the mutation positions and were saturated at the mutations found in the 1 st generation expandase hits. Additionally, a universal forward and reverse primer was designed in which an Nde ⁇ and ⁇ /s/l site were introduced respectively. This facilitated cloning into Penicillium expression vector for testing of the mutant expandases in vivo. The library was grown and expression of the expandase was induced as described in the materials and methods section. The formation of ad-7-ADCA was determined using NMR as described in the materials and methods section.
• mutant expandases were identified which exhibited an improvement factor of their ad-6-APA expandase up to 4,5-fold (compared to the wild type expandase of S. clavuligerus - SEQ ID No 1.). These mutants are designated H501 - H508 (see Table 3).
• the activity towards Pen-G of the various expandase mutants tested was either the same as the wild type expandase (improvement factor is 1) or improved up to 8-fold.
• the data further show that there is no correlation whatsoever between the improvement factors obtained for a single mutant with ad-6-APA and Pen-G as a substrate.
• the ratio between the respective improvement factors for ad-6-APA and Pen-G vary in a range from 0.1 (e.g. H654) to 1.2 (e.g. H503).
• Table 3 shows that 46 mutant expandases have been obtained which have improvement factors in the range of 1.5 to 10.6-fold.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Health & Medical Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Enzymes And Modification Thereof (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=34940295

Family Applications (1)

Country Status (5)

Families Citing this family (2)

Family Cites Families (2)

• 2006
  • 2006-04-10 BR BRPI0613004-6A patent/BRPI0613004A2/pt not_active IP Right Cessation
  • 2006-04-10 WO PCT/EP2006/061479 patent/WO2007006593A2/en not_active Application Discontinuation
  • 2006-04-10 CN CNA2006800255771A patent/CN101300360A/zh active Pending
  • 2006-04-10 KR KR1020087000778A patent/KR20080028924A/ko not_active Application Discontinuation
  • 2006-04-10 EP EP06725677A patent/EP1902140A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events